VHL and nonpapillary renal cell carcinoma: Moreover, drugs targeting the VHL–HIF–VEGF pathway, such as sunitinib, sorafenib and axitinib, have been shown to benefit patients with ccRCC, becoming the standard treatment for patients in the advanced stages of ccRCC (3).